Childhood predictors of antipsychotic use among young people in finland

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 9, 2012, Pages 964-971

  Gyllenberg, David ^a,b   Sourander, Andre ^b   Helenius, Hans ^c   Sillanmäki, Lauri ^b   Huttunen, Jukka ^b   Piha, Jorma ^b   Kumpulainen, Kirsti ^d   Tamminen, Tuula ^e   Moilanen, Irma ^f   Almqvist, Fredrik ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f UNIVERSITY OF OULU   (Finland)

Author keywords

Antipsychotic drugs; Epidemiology; Follow up studies; Pharmacoepidemiology

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR DISORDER; CHILDHOOD DISEASE; DEPRESSION; DRUG USE; EDUCATIONAL STATUS; FEMALE; FINLAND; FOLLOW UP; HOME ENVIRONMENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; PARENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF REPORT;

ADOLESCENT; ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; CHILD; FEMALE; FINLAND; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; MOOD DISORDERS; PSYCHOTIC DISORDERS; REGISTRIES; SEX FACTORS; YOUNG ADULT;

EID: 84865861895     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3265     Document Type: Article

References (47)

1. Zoega H, Baldursson G, Hrafnkelsson B, Almarsdottir AB, Valdimarsdottir U, Halldorsson M. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol 2009; 19: 757-764. DOI: 10.1089/cap.2009.0003.
2. Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010; 121: 4-10. DOI: 10.1111/j.1600-0447.2009.01425.x.
3. Alessi-Severini S, Biscontri RG, Collins DM, Kozyrskyj A, Sareen J, Enns MW. Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006. Psychiatr Serv 2008; 59: 547-553. DOI: 10.1176/appi.ps.59.5.547.
4. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Risperidone disruptive behavior study group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337-1346.
5. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry 2007; 16: 104-120. DOI: 10.1007/s00787-006-0580-1.
6. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010; 67: 26-36. DOI: 10.1001/archgenpsychiatry.2009.175.
7. Domino ME, Swartz MS. Who are the new users of antipsychotic medications? Psychiatr Serv 2008; 59: 507-514. DOI: 10.1176/appi.ps.59.5.507.
8. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 2007; 64: 1032-1039. DOI: 10.1001/archpsyc.64.9.1032.
9. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63: 679-685. DOI: 10.1001/archpsyc.63.6.679.
10. Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and axis II comparison subjects followed prospectively for 6years. J Clin Psychiatry 2004; 65: 28-36.
11. Wine JN, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother 2009; 43: 707-713. DOI: 10.1345/aph.1L320.
12. McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry 2009; 70: 1206-1212. DOI: 10.4088/JCP.08r04472.
13. International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. Br J Psychiatry Suppl 2005; 48: s120-s124. DOI: 10.1192/bjp.187.48.s120.
14. Kalverdijk LJ, Tobi H, van den Berg PB, et al. Use of antipsychotic drugs among Dutch youths between 1997 and 2005 Psychiatr Serv 2008; 59: 554-560. DOI: 10.1176/appi.ps.59.5.554.
15. Rani F, Murray ML, Byrne PJ, Wong IC. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008; 121: 1002-1009. DOI: 10.1542/peds.2007-2008.
16. Kaye JA, Bradbury BD, Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. Br J Clin Pharmacol 2003; 56: 569-575.
17. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47: 9-20. DOI: 10.1097/chi.0b013e31815b5cb1.
18. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337-345.
19. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
20. Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 2011; 21: 621-645.
21. Gyllenberg D, Sourander A. Psychotropic drug and polypharmacy use among adolescents and young adults: findings from the Finnish 1981 Nationwide Birth Cohort Study. Nord J Psychiatry 2012; Epub ahead of print Jan 3. DOI: 10.3109/08039488.2011.644809
22. Almqvist F, Ikäheimo K, Kumpulainen K, et al. Design and subjects of a Finnish epidemiological study on psychiatric disorders in childhood. Eur Child Adolesc Psychiatry 1999; 8 Suppl 4: 3-6.
23. Sourander A, Ronning J, Brunstein-Klomek A, et al. Childhood bullying behavior and later psychiatric hospital and psychopharmacologic treatment: findings from the Finnish 1981 Birth Cohort Study. Arch Gen Psychiatry 2009; 66: 1005-1012. DOI: 10.1001/archgenpsychiatry.2009.122.
24. Rutter M, Tizard J, Whitmore K (eds). Education, Health and Behaviour. Longman; London, 1970.
25. Rutter M. A children's behaviour questionnaire for completion by teachers: preliminary findings. J Child Psychol Psychiatry 1967; 8: 1-11.
26. Kresanov K, Tuominen J, Piha J, Almqvist F. Validity of child psychiatric screening methods. Eur Child Adolesc Psychiatry 1998; 7: 85-95.
27. Kovacs M. Children's Depression Inventory, CDI, Manual. Multi-Health Systems Inc.: Ontario, 1992.
28. Costello EJ, Angold A. Scales to assess child and adolescent depression: checklists, screens, and nets. J Am Acad Child Adolesc Psychiatry 1988; 27: 726-737.
29. Sourander A, Klomek AB, Niemelä S, et al. Childhood predictors of completed and severe suicide attempts: findings from the Finnish 1981 Birth Cohort Study. Arch Gen Psychiatry 2009; 66: 398-406. DOI: 10.1001/archgenpsychiatry.2009.21.
30. Gyllenberg D, Sourander A, Niemelä S, et al. Childhood predictors of later psychiatric hospital treatment: findings from the Finnish 1981 Birth Cohort Study. Eur Child Adolesc Psychiatry 2010; 19: 823-833. DOI: 10.1007/s00787-010-0129-1.
31. National Social Insurance Institution. Statistical yearbook the social insurance institution. www.kela.fi/it/kelasto/kelasto.nsf/alias/Vk_06_pdf (accessed May 2010).
32. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994; 10: 405-411.
33. Gyllenberg D, Sourander A, Niemelä S, et al. Childhood predictors of use and costs of antidepressant medication by age 24 years: findings from the Finnish nationwide 1981 Birth Cohort Study. J Am Acad Child Adolesc Psychiatry 2011; 50: 406-415. DOI: 10.1016/j.jaac.2010.12.016.
34. Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007; 64: 19-28. DOI: 10.1001/archpsyc.64.1.19.
35. Zito JM, Safer DJ, Berg LT, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008. DOI: 10.1186/1753-2000-2-26.
36. Autti-Rämö I, Seppänen J, Raitasalo R, Martikainen JE, Sourander A. Increase in use of psychotropics among adolescents and young adults since the beginning of the 21st century. Suom Lääkäril 2009; 64: 477-482.
37. Curtis LH, Masselink LE, Ostbye T, et al. Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Arch Pediatr Adolesc Med 2005; 159: 362-366. DOI: 10.1001/archpedi.159.4.362.
38. Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005; 44: 548-556.
39. Blanz B, Schmidt MH. Preconditions and outcome of inpatient treatment in child and adolescent psychiatry. J Child Psychol Psychiatry 2000; 41: 703-712.
40. Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC, Ray WA. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr 2006; 6: 79-83. DOI: 10.1016/j.ambp.2005.11.002.
41. Cyranowski JM, Frank E, Young E, Shear MK. Adolescent onset of the gender difference in lifetime rates of major depression: a theoretical model. Arch Gen Psychiatry 2000; 57: 21-27.
42. Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton R. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. Arch Gen Psychiatry 2003; 60: 709-717. DOI: 10.1001/archpsyc.60.7.709.
43. Olin SS, John RS, Mednick SA. Assessing the predictive value of teacher reports in a high risk sample for schizophrenia: a ROC analysis. Schizophr Res 1995; 16: 53-66.
44. Done DJ, Crow TJ, Johnstone EC, Sacker A. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ 1994; 309: 699-703.
45. Zahn-Waxler C, Shirtcliff EA, Marceau K. Disorders of childhood and adolescence: gender and psychopathology. Annu Rev Clin Psychol 2008; 4: 275-303. DOI: 10.1146/annurev.clinpsy.3.022806.091358.
46. Sourander A. Risperidone for treatment of childhood schizophrenia. Am J Psychiatry 1997; 154: 1476.
47. Bryden KE, Carrey NJ, Kutcher SP. Update and recommendations for the use of antipsychotics in early-onset psychoses. J Child Adolesc Psychopharmacol 2001; 11: 113-130. DOI: 10.1089/104454601750284027.